SELLAS Life Sciences Group (NASDAQ:SLS) Announces Earnings Results

SELLAS Life Sciences Group (NASDAQ:SLS) issued its quarterly earnings results on Tuesday. The company reported ($0.05) EPS for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.01, FiscalAI reports.

SELLAS Life Sciences Group Stock Down 0.6%

Shares of SELLAS Life Sciences Group stock traded down $0.03 on Tuesday, hitting $5.22. The stock had a trading volume of 2,823,922 shares, compared to its average volume of 7,219,854. SELLAS Life Sciences Group has a one year low of $1.36 and a one year high of $6.14. The stock has a market cap of $963.26 million, a price-to-earnings ratio of -20.88 and a beta of 2.24. The stock’s 50-day simple moving average is $4.95 and its two-hundred day simple moving average is $3.61.

Wall Street Analysts Forecast Growth

SLS has been the topic of a number of recent research reports. Maxim Group increased their price target on shares of SELLAS Life Sciences Group from $7.00 to $10.00 and gave the company a “buy” rating in a research report on Thursday, March 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a research report on Tuesday, April 21st. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $10.00.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. BNP Paribas Financial Markets grew its holdings in shares of SELLAS Life Sciences Group by 89.2% in the third quarter. BNP Paribas Financial Markets now owns 19,724 shares of the company’s stock worth $32,000 after purchasing an additional 9,299 shares during the last quarter. Beacon Pointe Advisors LLC bought a new position in shares of SELLAS Life Sciences Group in the fourth quarter worth approximately $38,000. Sei Investments Co. bought a new position in shares of SELLAS Life Sciences Group in the third quarter worth approximately $43,000. Great Valley Advisor Group Inc. bought a new position in shares of SELLAS Life Sciences Group in the second quarter worth approximately $44,000. Finally, Equitable Holdings Inc. grew its holdings in shares of SELLAS Life Sciences Group by 58.6% in the third quarter. Equitable Holdings Inc. now owns 27,060 shares of the company’s stock worth $44,000 after purchasing an additional 10,000 shares during the last quarter. Institutional investors own 17.38% of the company’s stock.

SELLAS Life Sciences Group Company Profile

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells.

The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.